Lynparza for soamtic breast cancer mutations – pro
There is clinical evidence regarding the effectiveness of this drug for this indication as published in the authoritative, peer-reviewed medical and scientific literature.I do not see testing for gbrca mutation, but there is a substantial overlaps in efficacy of olaparib in this spectrum of mutations. Advanced cancer patients harboring somatic or germline BRCA1/2 mutations respond to treatment with olaparib. A small study by George et al a subgroup analysis in those with somatic not germline BRCA mutations indicated a comparable benefit.
S. Jaris et al, Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. ESMO Open
Volume 8, Issue 6, December 2023, 102041
George A, Banerjee S, Kaye S. Olaparib and somatic BRCA mutations. Oncotarget. 2017 Jul 4;8(27):43598-43599. doi: 10.18632/oncotarget.18419. PMID: 28611314; PMCID: PMC5546426.
Lynparza, Prescribing Informaiton 2025